Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (NASDAQ: CERS) is a biomedical products company focused on blood transfusion safety through its INTERCEPT Blood System and related technologies. This news page aggregates company announcements, financial updates, clinical milestones, and partnership news that Cerus releases through channels such as Business Wire and SEC-furnished press releases.
Readers can find coverage of quarterly and annual financial results, where Cerus reports product revenue from INTERCEPT platelet, plasma, and INTERCEPT Fibrinogen Complex (IFC) sales, along with government contract revenue tied to research and development programs. These releases often include updated product revenue guidance ranges and commentary on commercial performance in various geographies.
The news flow also highlights clinical and regulatory developments, including progress of the INTERCEPT red blood cell system in late-stage clinical development, Phase 3 trials such as RedeS, and regulatory review activities in Europe and the United States. Updates on the INT200 LED-based illumination device and development of lyophilized IFC (LyoIFC), supported by U.S. Department of Defense funding, are also featured.
In addition, Cerus issues news about strategic collaborations and industry engagement, such as group purchasing agreements with organizations like Blood Centers of America and participation in professional meetings, workshops, and conferences in transfusion medicine. These items describe efforts to expand access to pathogen-protected blood components and to share data on INTERCEPT technologies.
Investors, clinicians, and other stakeholders can use this page to follow Cerus’ latest disclosures on product adoption, revenue trends, government-supported projects, and scientific presentations related to blood safety and pathogen reduction.
Cerus Corporation (Nasdaq: CERS) announced participation in two upcoming conferences: the Stifel Virtual Healthcare Conference on November 16 at 1:20 PM ET and the Stephens Annual Investment Conference on November 19 at 3:00 PM ET. Key executives, William ‘Obi’ Greenman and Kevin D. Green, will represent the company. A live webcast will be available on the Investor Relations page of Cerus' website, with replays accessible for about two weeks. Cerus focuses on blood safety technologies through its INTERCEPT Blood System.
Cerus Corporation (Nasdaq: CERS) reported Q3 2020 total revenue of $29.2 million, up 27.8% from $22.8 million year-over-year, driven by robust platelet kit sales in the U.S. and the EMEA region. Product revenue reached $23.6 million, a 31% increase, while government contract revenue rose to $5.6 million, a 15.7% increase. Cash reserves at quarter-end stood at $135.1 million. The company narrowed its 2020 product revenue guidance to $89 million to $91 million, attributing the adjustment to COVID-19's impact on blood supply.
Cerus Corporation (Nasdaq:CERS) will release its third quarter 2020 financial results on October 29, 2020, after market close. A conference call will follow at 4:30 P.M. ET to discuss the results and general business outlook. Investors can access the live webcast via Cerus' Investor Relations page. The INTERCEPT Blood System, which has received CE Mark and FDA approval, is the company's primary focus for ensuring safe blood products. The INTERCEPT Red Blood Cell system is currently in clinical development.
Cerus Corporation (Nasdaq:CERS) has secured an $11.1 million contract with the U.S. FDA to develop next-gen compounds for optimizing pathogen reduction (PR) treatment of whole blood. This initiative aims to enhance blood safety and reduce transfusion-transmitted infections. Cerus' program aligns with FDA's proactive strategies for blood safety, complementing its existing products for platelets and plasma. The potential breakthrough in whole blood PR technology could offer comprehensive safety solutions for transfusable blood components.
Cerus Corporation (Nasdaq:CERS) announced notable participation at the AABB 2020 Virtual Annual Meeting, taking place from October 3-5. The event will highlight vital advancements in transfusion medicine, including 17 abstracts presented by Cerus, featuring one oral presentation on optimizing platelet supply. Key focus areas include new FDA guidance on bacterial risk control for platelets and the economic impacts of implementing INTERCEPT Blood System strategies. Cerus remains committed to improving blood safety and is poised for advancements in its clinical studies.